title: [A case of inflammatory breast cancer achieving pathological complete response by primary systemic therapy with CEF (cyclophosphamide, epirubicin, 5-fluorouracil) followed by docetaxel].
abstract: A 48-year-old woman noticed her right breast swelling since a few weeks earlier. Rigidity in the AC area, hotness, swelling and peau d'orange appearance of the right whole breast were recognized. She was diagnosed as inflammatory breast cancer clinically and invasive ductal carcinoma with lymphatic invasion pathologically. The patient underwent primary systemic therapy with 4 cycles of CEF (cyclophosphamide 500 mg/m(2), epirubicin 100 mg/m(2), 5-fluorouracil 500 mg/m(2)) followed by 4 cycles of docetaxel (70 mg/m(2)). The effect of chemotherapy showed a partial response evaluated by mammography and ultrasonography, and complete response by MRI before surgery. Right mastectomy with level II lymph node dissection was performed. Pathologically, complete response was confirmed (pCR). Although IBC has been known for its poor outcome, this case suggests IBC will show a better prognosis by chemotherapy such as CEF followed by docetaxel.
authors.affiliation: Dept. of Breast Surgery, Sagara Hospital.
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Sagara
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Rai
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Sagara
authors.forename: Shugo
authors.initials: S
authors.lastname: Tamada
authors.forename: Shinsaku
authors.initials: S
authors.lastname: Tsuchimochi
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Takahama
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Matsuyama
authors.forename: Mitsutake
authors.initials: M
authors.lastname: Ando
authors.forename: Yasuyo
authors.initials: Y
authors.lastname: Ooi
authors.forename: Yoshiatsu
authors.initials: Y
authors.lastname: Sagara
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D000077143:Docetaxel; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D008327:Mammography; D008875:Middle Aged; D012074:Remission Induction; D043823:Taxoids / Q000008:administration & dosage; D014057:Tomography, X-Ray Computed; D016217:Ultrasonography, Mammary
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D015251:Epirubicin; D003520:Cyclophosphamide; D005472:Fluorouracil